The role of PCDH19 in refractory status epilepticus

Marina Trivisano1, Nicola Specchio1

  • 1Rare and Complex Epilepsy Unit, Department of Neuroscience and Neurorehabilitation, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Epilepsy & Behavior : E&B
|November 4, 2019
PubMed

Insights

PCDH19-Girls Clustering Epilepsy (GCE) frequently involves status epilepticus (SE), a severe seizure type often resistant to treatment. This review highlights the need for further research into SE in GCE to improve patient outcomes.

Area of Science:

  • Neurology
  • Genetics
  • Epilepsy Research

Background:

  • PCDH19-Girls Clustering Epilepsy (GCE) is an infantile-onset epileptic syndrome.
  • It is characterized by clustered, fever-induced seizures, intellectual disability, and autistic features.
  • Seizures can progress to status epilepticus (SE), often refractory to standard treatments.

Purpose of the Study:

  • To review the literature on PCDH19-GCE.
  • To define the prevalence, semiology, treatments, and outcomes of SE in PCDH19-GCE.
  • To identify knowledge gaps and suggest future research directions.

Main Methods:

  • Comprehensive literature review of PubMed and EMBASE databases (January 2008 - July 2019).
  • Selection and assessment of 59 full-text articles.
  • Collection and analysis of data from 269 PCDH19-GCE cases, focusing on 85 with reported SE.

Main Results:

  • SE prevalence in PCDH19-GCE is 31.5% (85 out of 269 cases).
  • Status epilepticus was refractory in 71.4% of cases (15 out of 21 with detailed data).
  • High comorbidity of intellectual disability and autism (90%) was observed in patients with SE.

Conclusions:

  • Status epilepticus is a significant complication of PCDH19-GCE, frequently refractory and associated with intellectual disability and autism.
  • Current understanding of SE semiology, EEG patterns, and treatment in PCDH19-GCE is limited.
  • A multicenter study focusing on SE characteristics is crucial to improve knowledge and patient outcomes.

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
536
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
467